BioSpace News Archive

On February 2, 2018, Premier Biotech Inc. was granted a coveted 510(k) clearance for the following drugs Amphetamine, Cocaine, Marijuana, Methamphetamine, Opiates and Phencyclidine from the Food and Drug Administration (FDA) for OralTox®.

CTI BioPharma Inc. reported financial results for the fourth quarter and full year ended December 31, 2017.

Protagonist Therapeutics, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2017 and provided an update on the company’s recent achievements.

Eisai Company, Ltd. and Merck announced that the companies have agreed upon a strategic collaboration for the worldwide co-development and co-commercialization of LENVIMA® (lenvatinib mesylate), an orally available tyrosine kinase inhibitor discovered by Eisai.

CryoLife, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2017.

Veloxis Pharmaceuticals A/S announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food & Drug Administration (FDA) seeking a new indication for ENVARSUS XR (tacrolimus extended-release tablets) for the prophylaxis of organ rejection in kidney transplant patients in combination with other immunosuppressants.